retatrutide weight loss results clinical trial 2024 2025 press release Lilly's retatrutide shows 28% weight loss Retatrutide Weight Loss Treatment Explained

Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors

If fatigue is the problem, morning injections may be preferable so the tired phase hits in the evening when you would be winding down anyway

Her words

Recently, there have been concerns of an increased risk of intestinal obstruction associated with GLP-1RAs [4,5,6,7,8,9,10,11,12,13]

Condition Location Conditions Locations Treatment Type Trial Phase Trial Status Paid Participation Trial Details Key Eligibility Criteria 263 Participants Needed Trial Details Key Eligibility Criteria 1538 Participants Needed Trial Details Key Eligibility Criteria 480 Participants Needed Trial Details Key Eligibility Criteria 800 Participants Needed Trial Details Key Eligibility Criteria 420 Participants Needed Trial Details Key Eligibility Criteria 390 Participants Needed Trial Details Key Eligibility Criteria 876 Participants Needed Trial Details Key Eligibility Criteria 960 Participants Needed Trial Details Key Eligibility Criteria 590 Participants Needed Trial Details Key Eligibility Criteria 600 Participants Needed Trial Details Key Eligibility Criteria 900 Participants Needed Trial Details Key Eligibility Criteria 5240 Participants Needed Trial Details Key Eligibility Criteria 700 Participants Needed Trial Details Key Eligibility Criteria 32000 Participants Needed Trial Details Key Eligibility Criteria 500 Participants Needed Trial Details Key Eligibility Criteria 734 Participants Needed Trial Details Key Eligibility Criteria 800 Participants Needed Trial Details Key Eligibility Criteria 1410 Participants Needed Trial Details Key Eligibility Criteria 450 Participants Needed Trial Details Key Eligibility Criteria 1023 Participants Needed "I've been struggling with ADHD and anxiety since I was 9 years old

TRIUMPH-4 (Retatrutide) - 28.7% Weight Loss Study design: 445 adults with obesity and knee osteoarthritis 68 weeks duration Published December 2025 Results at 12mg: Average weight loss: 28.7% (32.3 kg / 71.2 lbs) 20% responders: 73.4% 25% responders: 58.6% SURMOUNT-1 (Tirzepatide) - 22.5% Weight Loss Study design: 2,539 adults with obesity 72 weeks duration Published June 2022 Results at 15mg: Average weight loss: 22.5% (24 kg / 52 lbs) 20% responders: 57% 25% responders: 43% STEP 1 (Semaglutide) - 14.9% Weight Loss Study design: 1,961 adults with obesity 68 weeks duration Published March 2021 Results at 2.4mg: Average weight loss: 14.9% (15.3 kg / 33.7 lbs) 20% responders: 32% 25% responders: 12% Head-to-Head Comparison Key findings: Retatrutide vs Semaglutide: 93% more weight loss (28.7% vs 14.9%) Tirzepatide vs Semaglutide: 51% more weight loss (22.5% vs 14.9%) Retatrutide vs Tirzepatide: 28% more weight loss (28.7% vs 22.5%) Practical example for 100kg (220 lb) person: Semaglutide: 14.9 kg loss (33 lbs) 85.1 kg (188 lbs) Tirzepatide: 22.5 kg loss (50 lbs) 77.5 kg (171 lbs) Retatrutide: 28.7 kg loss (63 lbs) 71.3 kg (157 lbs) Mechanism of Action: Single vs Dual vs Triple Semaglutide: Single Agonist (GLP-1 Only) Targets one receptor: GLP-1: Reduces appetite, slows digestion, enhances insulin Brands: Ozempic (diabetes, 1mg weekly) Wegovy (weight loss, 2.4mg weekly) Effectiveness: 14.9% average weight loss Tirzepatide: Dual Agonist (GLP-1 + GIP) Targets two receptors: GLP-1: Appetite suppression GIP: Insulin sensitivity, metabolic improvement Brands: Mounjaro (diabetes, up to 15mg) Zepbound (weight loss, up to 15mg) Effectiveness: 22.5% average weight loss51% better than Semaglutide Retatrutide: Triple Agonist (GLP-1 + GIP + Glucagon) Targets three receptors: GLP-1: Appetite control GIP: Metabolic efficiency Glucagon: Energy expenditure, fat burning Status: Investigational (not yet FDA-approved) Effectiveness: 28.7% average weight loss93% better than Semaglutide Mechanism Comparison Table Why more targets = more weight loss: 1 target (Sema): Reduces calories in 15% weight loss 2 targets (Tirz): Reduces calories in + improves metabolism 22.5% weight loss 3 targets (Reta): Reduces calories in + improves metabolism + increases calories out 29% weight loss Safety and Side Effects Comparison Common Side Effects Key findings: Tirzepatide has the best tolerability profile: Lowest nausea (31% vs 43-44%) Lowest discontinuation among newer drugs (6.2%) Better GI side effects than either Retatrutide or Semaglutide Semaglutide has lowest discontinuation overall: Only 6.9% discontinued (best retention) Five years of real-world safety data Retatrutide has highest discontinuation: 18.2% discontinued (likely due to glucagon component) Limited safety data (investigational) Dosing Schedules Semaglutide (Wegovy): Week 1-4: 0.25mg Week 5-8: 0.5mg Week 9-12: 1mg Week 13-16: 1.7mg Week 17+: 2.4mg Tirzepatide (Zepbound): Week 1-4: 2.5mg Week 5-8: 5mg Week 9-12: 10mg Week 13+: 15mg Retatrutide (expected): Week 1-4: 2mg Week 5-8: 4mg Week 9-12: 6mg Week 13-16: 9mg Week 17+: 12mg (confirmed from TRIUMPH-4 Phase 3 protocol, Lilly press release December 2025) FDA Approval Status and Availability Semaglutide: First to Market (2021) FDA approval: 2017: Ozempic approved for diabetes June 2021: Wegovy approved for weight loss 5 years market experience Current availability: Available by prescription nationwide Cost: ~$1,349/month without insurance Tirzepatide: Newest Approved Option (2023) FDA approval: May 2022: Mounjaro approved for diabetes November 2023: Zepbound approved for weight loss 3 years market experience Current availability: Available by prescription nationwide Cost: ~$1,060/month without insurance Retatrutide: Investigational (2027-2028) Current status: Not FDA-approved (Phase 3 trials ongoing) Not available for prescription Access limited to clinical trial participants Expected timeline: Q4 2026: NDA filing expected 2027: FDA review Late 2027: Possible approval 2028: Market launch if approved TRIUMPH trial program: 2 of 8 trials complete (TRIUMPH-4: 28.7%, TRIUMPH-1: 28.3%) Cost and Insurance Coverage Monthly Costs (Without Insurance) Insurance Coverage For diabetes: Both Semaglutide (Ozempic) and Tirzepatide (Mounjaro) typically covered with prior authorization